| Year |
Citation |
Score |
| 2024 |
Klein AK, Austin EW, Cunningham MJ, Dvorak D, Gatti S, Hulls SK, Kiss L, Kruegel AC, Marek GJ, Papp M, Sporn J, Hughes ZA. GM-1020: a novel, orally bioavailable NMDA receptor antagonist with rapid and robust antidepressant-like effects at well-tolerated doses in rodents. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 38177696 DOI: 10.1038/s41386-023-01783-1 |
0.319 |
|
| 2020 |
Marek GJ, Salek AA. Extending the specificity of differential-reinforcement-of-low rate 72-s (DRL 72-s) behavior for screening antidepressant-like effects of glutamatergic clinically validated anxiolytic or antidepressant drugs in rats. The Journal of Pharmacology and Experimental Therapeutics. PMID 32265323 DOI: 10.1124/jpet.119.264069 |
0.444 |
|
| 2018 |
Marek GJ, Ramos BP. β-Adrenergic Receptor Activation Suppresses the Rat Phenethylamine Hallucinogen-Induced Head Twitch Response: Hallucinogen-Induced Excitatory Post-synaptic Potentials as a Potential Substrate. Frontiers in Pharmacology. 9: 89. PMID 29472863 DOI: 10.3389/fphar.2018.00089 |
0.318 |
|
| 2017 |
Marek GJ. Interactions of Hallucinogens with the Glutamatergic System: Permissive Network Effects Mediated Through Cortical Layer V Pyramidal Neurons. Current Topics in Behavioral Neurosciences. PMID 28831734 DOI: 10.1007/7854_2017_480 |
0.325 |
|
| 2015 |
Marek GJ. When is a Proof-of-Concept (POC) not a POC? Pomaglumetad (LY2140023) as a Case Study for Antipsychotic Efficacy. Current Pharmaceutical Design. 21: 3788-96. PMID 26044978 DOI: 10.2174/1381612821666150605105632 |
0.303 |
|
| 2013 |
Wright RA, Johnson BG, Zhang C, Salhoff C, Kingston AE, Calligaro DO, Monn JA, Schoepp DD, Marek GJ. CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [³H]LY459477 autoradiography. Neuropharmacology. 66: 89-98. PMID 22313530 DOI: 10.1016/j.neuropharm.2012.01.019 |
0.318 |
|
| 2012 |
Marek GJ. Activation of adenosine₁ receptors induces antidepressant-like, anti-impulsive effects on differential reinforcement of low-rate 72-s behavior in rats. The Journal of Pharmacology and Experimental Therapeutics. 341: 564-70. PMID 22323824 DOI: 10.1124/jpet.112.191718 |
0.421 |
|
| 2011 |
Fell MJ, Witkin JM, Falcone JF, Katner JS, Perry KW, Hart J, Rorick-Kehn L, Overshiner CD, Rasmussen K, Chaney SF, Benvenga MJ, Li X, Marlow DL, Thompson LK, Luecke SK, ... ... Marek GJ, et al. N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. The Journal of Pharmacology and Experimental Therapeutics. 336: 165-77. PMID 20947638 DOI: 10.1124/Jpet.110.172957 |
0.373 |
|
| 2010 |
Nikiforuk A, Popik P, Drescher KU, van Gaalen M, Relo AL, Mezler M, Marek G, Schoemaker H, Gross G, Bespalov A. Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats. The Journal of Pharmacology and Experimental Therapeutics. 335: 665-73. PMID 20739457 DOI: 10.1124/Jpet.110.170506 |
0.306 |
|
| 2010 |
Mezler M, Geneste H, Gault L, Marek GJ. LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Current Opinion in Investigational Drugs (London, England : 2000). 11: 833-45. PMID 20571979 |
0.329 |
|
| 2009 |
Marek GJ. Activation of adenosine(1) (A(1)) receptors suppresses head shakes induced by a serotonergic hallucinogen in rats. Neuropharmacology. 56: 1082-7. PMID 19324062 DOI: 10.1016/j.neuropharm.2009.03.005 |
0.324 |
|
| 2008 |
Ardayfio PA, Benvenga MJ, Chaney SF, Love PL, Catlow J, Swanson SP, Marek GJ. The 5-hydroxytryptamine2A receptor antagonist R-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) attenuates impulsivity after both drug-induced disruption (dizocilpine) and enhancement (antidepressant drugs) of differential-reinforcement-of-low-rate 72-s behavior in the rat. The Journal of Pharmacology and Experimental Therapeutics. 327: 891-7. PMID 18772320 DOI: 10.1124/jpet.108.143370 |
0.341 |
|
| 2008 |
Zhang C, Marek GJ. AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32: 62-71. PMID 17728034 DOI: 10.1016/j.pnpbp.2007.07.009 |
0.307 |
|
| 2007 |
Witkin JM, Marek GJ, Johnson BG, Schoepp DD. Metabotropic glutamate receptors in the control of mood disorders. Cns & Neurological Disorders Drug Targets. 6: 87-100. PMID 17430147 DOI: 10.2174/187152707780363302 |
0.314 |
|
| 2007 |
Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039). The Journal of Pharmacology and Experimental Therapeutics. 321: 308-17. PMID 17204749 DOI: 10.1124/jpet.106.110809 |
0.33 |
|
| 2006 |
Marek GJ, Wright RA, Schoepp DD. 5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740. Neuroscience Letters. 403: 256-60. PMID 16759803 DOI: 10.1016/j.neulet.2006.05.021 |
0.311 |
|
| 2005 |
O'Donnell JM, Marek GJ, Seiden LS. Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule. Neuroscience and Biobehavioral Reviews. 29: 785-98. PMID 15893376 DOI: 10.1016/j.neubiorev.2005.03.018 |
0.378 |
|
| 2003 |
Marek GJ. Behavioral evidence for mu-opioid and 5-HT2A receptor interactions. European Journal of Pharmacology. 474: 77-83. PMID 12909198 DOI: 10.1016/s0014-2999(03)01971-x |
0.355 |
|
| 2002 |
DD DD, Marek GJ. Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Current Drug Targets. Cns and Neurological Disorders. 1: 215-25. PMID 12769628 |
0.369 |
|
| Show low-probability matches. |